May 26, 2024

Angioedema Treatment Market High Growth Opportunities, Emerging Trends, Industry Review, Forecast Till 2030

The growing demand for therapeutic drugs to treat angioedema and increasing prevalence of hereditary angioedema are some of the key factors propelling the growth of the angioedema treatment market. Hereditary angioedema is a rare genetic disorder that causes recurrent episodes of severe swelling in various body parts like hands, feet, intestines, face, or airways. The swelling occurs due to increased permeability of blood vessels triggered by deficient or dysfunctional C1-inhibitor protein in blood.

The global Angioedema Treatment Market is estimated to be valued at US$ 470.4 Mn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/angioedema-treatment-market-1371

Market key trends:

The increasing R&D activities for novel drug development is one of the major trends witnessed in the angioedema treatment market. Many pharmaceutical companies are actively investing in research to develop novel therapies for hereditary angioedema. For instance, Pharming Group NV along with Sobi, is developing recombinant human C1-inhibitor Ruconest to treat acute angioedema attacks. Additionally, CSL Behring is developing HAEGARDA, a subcutaneously administered C1-inhibitor concentrate for the prevention of angioedema attacks in patients with HAE. Such novel drug launches are expected to aid the market growth over the forecast period.

Porter’s Analysis

Threat of new entrants: The threat of new entrants is moderate as the R&D and clinical trial requirements for new drugs make market entry difficult and capital intensive. However, large pharmaceutical companies can leverage existing infrastructure and resources to develop new drugs.

Bargaining power of buyers: The bargaining power of buyers is moderate. While larger buyers such as government organizations and private insurers can negotiate lower prices, individual consumers have little influence over prices.

Bargaining power of suppliers: The bargaining power of suppliers is moderate. Key raw material suppliers face competition and have limited differentiation in their offerings. Suppliers of innovative drug delivery technologies may wield more bargaining power.

Threat of new substitutes: The threat of new substitutes is low as there are limited treatment options currently available for angioedema. However, companies are developing novel drug formulations, devices, and therapies that can substitute existing treatment regimens.

Competitive rivalry: The competitive rivalry is high due to the presence of many large pharmaceutical companies focusing on developing newer drugs and treatment regimens for angioedema. Companies compete based on product efficacy, safety profile, dosing convenience and cost.

Key Takeaways

The global angioedema treatment market is expected to witness high growth.

The market in North America currently dominates due to high prevalence of angioedema and favorable reimbursement policies. However, the Asia Pacific region is expected to grow at the fastest pace during the forecast period driven by growing disease awareness, increasing healthcare spending and presence of generic drug manufacturers in the region.

Key players operating in the angioedema treatment market are Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Virbac S.A., Ceva Santé Animale, Elanco Animal Health, Bimeda, Aurobindo Pharma Limited, and Teva Pharmaceutical Industries Ltd. These players are focusing on new drug launches and acquisitions to strengthen their product portfolios and market position. For instance, in 2022, Teva Pharmaceutical Industries Ltd launched generic version of Haegarda (C1 esterase inhibitor subcutaneous ) for prevention of angioedema attacks in adolescent and adult patients.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it